<DOC>
	<DOCNO>NCT02474212</DOCNO>
	<brief_summary>To evaluate pharmacokinetics thromboprophylactic agent enoxaparin postoperative cardiac surgery patient compare plasma anti-Xa activity enoxaparin administer either continuous intravenous infusion subcutaneous bolus daily . After informed consent , 80 elective pump CABG patient clinical indication post-operative thromboprophylaxis study Tampere University Hospital Heart Central . The study consist two independent part . In first part study twenty elective CABG patient randomise receive subcutaneous enoxaparin ( Klexane® , Sanofi-Aventis ) 40 mg thromboprophylaxis every 24 hour three day . Another twenty patient randomise receive dose enoxaparin ( 40 mg ) daily continuous intravenous infusion three day ( 72 hour ) . In second part study twenty elective CABG patient randomise receive subcutaneous enoxaparin ( Klexane® , Sanofi-Aventis ) 0,5 mg/ kg twice day . Another twenty patient randomise receive enoxaparin 1 mg/kg daily continuous intravenous infusion three day ( 72 hour ) .</brief_summary>
	<brief_title>: Pharmacokinetics Enoxaparin After Coronary Artery Bypass Graft Surgery</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<criteria>BMI 1830 kg/m2 Elective onpump CABG operation Indication postoperative pharmacological thromboprophylaxis Written inform consent obtain patient his/her legal representative . Other indication anticoagulant therapy thromboprophylaxis Known heparin induce thrombocytopenia ( HIT ) , hypersensitivity enoxaparin heparin Any longterm anticoagulant medication , expect lowdose aspirin Major bleeding within last week unless definitively treat Blood platelet count &lt; 20 , PTT &lt; 20 % INR &gt; 1.7 GFR less 30 ml/min/1.73 m2 estimate serum creatinine apply CockcroftGault equation 13 chronic dialysis Known HIV , HBV , HCV infection Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Venous thromboembolism</keyword>
	<keyword>pulmonary embolism</keyword>
	<keyword>thromboprophylaxis</keyword>
	<keyword>anticoagulant</keyword>
	<keyword>anti-FXa</keyword>
	<keyword>low-molecular weight heparin</keyword>
	<keyword>enoxaparin</keyword>
</DOC>